These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 18242)
1. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Johnson DA Br J Hosp Med; 1977 Jun; 17(6):546-58. PubMed ID: 18242 [No Abstract] [Full Text] [Related]
2. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. Dencker SJ J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744 [TBL] [Abstract][Full Text] [Related]
3. Early hospital experience with fluphenazine decanoate. Small JG; Kellams J Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058 [TBL] [Abstract][Full Text] [Related]
5. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. Johnson DA J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743 [TBL] [Abstract][Full Text] [Related]
6. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics. Möller HJ; Kissling W Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841 [No Abstract] [Full Text] [Related]
7. Antipsychotic medication: clinical guidelines for maintenance therapy. Johnson DA J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281 [TBL] [Abstract][Full Text] [Related]
8. Depot neuroleptic therapy: an underutilized treatment option. Glazer WM; Kane JM J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569 [TBL] [Abstract][Full Text] [Related]
9. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective. Hogarty GE J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746 [TBL] [Abstract][Full Text] [Related]
10. [Prolonged action neuroleptics (review of the foreign literature)]. Obukhov GA Zh Nevropatol Psikhiatr Im S S Korsakova; 1975; 75(2):285-95. PubMed ID: 235182 [No Abstract] [Full Text] [Related]
15. Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430 [TBL] [Abstract][Full Text] [Related]
16. The depot fluphenazines: a reappraisal after 10 years' clinical experience. Ayd FJ Am J Psychiatry; 1975 May; 132(5):491-500. PubMed ID: 1091162 [No Abstract] [Full Text] [Related]
17. Compliance in the long-term treatment of schizophrenia. Kane JM; Borenstein M Psychopharmacol Bull; 1985; 21(1):23-7. PubMed ID: 2858907 [No Abstract] [Full Text] [Related]
18. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia. Carney MW; Sheffield BF Br J Psychiatry; 1976 Nov; 129():476-81. PubMed ID: 990663 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of schizophrenia]. Houy-Durand E; Thibaut F Rev Prat; 2002 Jun; 52(11):1213-20. PubMed ID: 12148207 [TBL] [Abstract][Full Text] [Related]
20. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial. Dencker SJ; Frankenberg K; Malm U; Zell B Acta Psychiatr Scand Suppl; 1973; 241():101-18. PubMed ID: 4147508 [No Abstract] [Full Text] [Related] [Next] [New Search]